Trigger Alert: Hemab’s $157M Series C
Capitalize on Hemab’s $157M Series C. Pitch CTMS & supply-chain automation. Grab decision-maker intel, pain points & your next touch.
Published on
Do not index
Do not index
🚀 Battle Card: Hemab Therapeutics
Quick trigger:
This Hemab Therapeutics sales trigger creates an opportunity to pitch CTMS and supply-chain automation solutions.
👤 Decision Maker in the News
- Benny Sorensen, MD, PhD, President & CEO 📧 bsorenson@hemab.com
💡 Why It Matters
- Oversubscribed Series C round boosts capacity to advance 5 clinical assets by 2025 and strengthens R&D runway. → Source
🎯 Core Pain Point
- Scaling clinical trial operations across multiple indications
- Establishing GMP manufacturing partnerships for novel antibody therapeutics
💰 What to Pitch
- Primary: Clinical Trial Management Software → Accelerate enrollment and data oversight
- Expansion: GMP Supply Chain Automation → Minimize batch failures and speed time to clinic
🗺️ Quick Context
- HQ: Cambridge, MA
- Employees: ≈ 65
- Rev: ≈ $2 M
- Website: hemab.com
🤼 Competitive Intel
Which other vendors you’ll probably face to win Hemab Therapeutics’ business.
- Veeva Systems — CTMS / eTMF
- Unique edge: Industry-leading validation and regulatory compliance
- Evaluated by Clinical Ops for integrated eTMF workflows
- Medidata — CTMS / eCOA
- Unique edge: Advanced analytics and patient engagement tools
- Evaluated by Head of R&D for trial optimization
- Oracle Health Sciences — Clinical Trial Management
- Unique edge: Scalable global platform with heavy data security
- Evaluated by IT for enterprise-grade support
- BioClinica — CTMS / Imaging Core Lab
- Unique edge: End-to-end imaging and clinical services
- Evaluated by Clinical Leads for imaging assay integration
✅ Do-Now Checklist
Connect with Benny Sorensen on LinkedIn (create or find his profile)
Reference this Hemab Therapeutics sales trigger in your first outreach email
Generate email + DM with the Copy-My-Prompt block (Step 7) and send first touch
Schedule follow-ups in CRM (Day 3 & Day 10)
Next Step
Capitalize on this Hemab Therapeutics sales trigger and get intel like this daily—no fluff, all pipeline.
Subscribe to NewsletterForLeads
🧠 Copy My Prompt for Personalized Cold Outreach
────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY = ❑❑
OFFER_BRIEF = ❑Clinical Trial Management Software❑
PROOF_METRIC = ❑≈ TBD❑
CTA_STYLE = ❑quick_call❑
TONE = ❑friendly❑
────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME = Benny
COMPANY = Hemab Therapeutics
DEPT = Clinical Ops
SIZE = ≈ TBD
BOTTLENECK = Scaling clinical trial operations across multiple indications
EVENT = Nets $157M Series C financing
DETAIL = oversubscribed $157M Series C round
PAIN = scaling clinical trial operations across multiple indications
SRC = https://vcnewsdaily.com/hemab-therapeutics/venture-capital-funding/mjrqthcyqc
SIM_CO = ≈ TBD
WIN_METRIC = ≈ TBD
NEXT_SIZE = ≈ TBD
EMP_EST = ≈ 65
REV_EST = ≈ $2M
────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.
Validate any ≈ guesses via SRC.
EMAIL (keep breaks):
Subject: ≈ TBD-person Clinical Ops
Benny—noticed your Clinical Ops team is ≈ TBD.
That’s when Scaling clinical trial operations across multiple indications slows growth.
We helped ≈ TBD fix this with Clinical Trial Management Software.
Result: ≈ TBD.
Quick call?
PS—next bottleneck hits ≈ TBD.
DM ≤45 words, TONE:
Saw your post about oversubscribed $157M Series C round — scaling clinical trial operations across multiple indications.
Clinical Trial Management Software. ≈ TBD.
Quick chat?